Death Ambivalence and Treatment Seeking: Suicidality in Opiate Addiction
Purpose of review
Rates of suicide and opiate overdose have recently skyrocketed in the USA. In light of impulsivity and impaired motivation common in people with substance use disorders, suicidality is common in addiction.
Chart review surveys indicate two primary suicidal populations that are important to distinguish for clinical practice and healthcare policy. One group is heavily composed of people with substance use disorders, in whom chronic compulsive use fosters a numb ambivalence about death (low death intentionality). Many of these individuals with opiate use disorder (OUD) exaggerate suicidality to get prompt psychiatric care to treat the OUD. The second group is composed of those who have comorbid psychiatric disorders and/or chronic pain who have a higher intent to die consistent with traditionally understood suicide risk factors.
We contend that easier access to outpatient opiate agonist treatment would avoid unnecessary hospitalizations for death-ambivalent OUD patients and for OUD patients in either group. First-line treatment with an opioid agonist has high potential to effectively treat suicidal ideation as a secondary benefit.
KeywordsOpiate use disorder Opiates Addiction Suicide Treatment Medication assisted therapy
Compliance with ethical standards
Conflict of interest
Stacey C. Conroy declares that she has no conflict of interest.
James M. Bjork declares that he has no conflict of interest.
Human and animal rights and informed consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Curtin SC, Warner M, Hedegaard H. Increase in suicide in the United States, 1999–2014. National Center for Health Statistics, US Centers for Disease Control and Prevention. Data Brief 2016;241:1–8.Google Scholar
- 10.•• Bennett AS, Elliott L, Golub A, Wolfson-Stofko B, Guarino H. Opioid-involved overdose among male Afghanistan/Iraq-Era U.S. military veterans: a multidimensional perspective. Subst Use Misuse. 2017;52:1701–11. Colorful article that encapsulates the mindset of the death-ambivalent, opiate-dependent patient.CrossRefPubMedGoogle Scholar
- 13.• Sharma A, Wolf DH, Ciric R, Kable JW, Moore TM, Vandekar SN, et al. Common dimensional reward deficits across mood and psychotic disorders: a connectome-wide association study. Am J Psychiatry. 2017;174:657–66. Important paper documenting neurocircuit abnormalities with motivation common across mental disorders.Google Scholar
- 14.Blum K, Braverman ER, Holder JM, Lubar JF, Monastra VJ, Miller D, et al. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J Psychoactive Drugs. 2000;32 Suppl:i–iv. 1–112Google Scholar
- 15.• Luijten M, Schellekens AF, Kühn S, Machielse MWJ, Sescousse G. Disruption of reward processing in addiction: an image-based meta-analysis of functional magnetic resonance imaging studies. JAMA Psychiatry. 2017; Seminal paper illustrating core deficits in motivation by non-substance rewards in substance abuse.Google Scholar
- 25.Martins SS, Fenton MC, Keyes KM, Blanco C, Zhu H, Storr CL. Mood and anxiety disorders and their association with non-medical prescription opioid use and prescription opioid-use disorder: longitudinal evidence from the National Epidemiologic Study on Alcohol and Related Conditions. Psychol Med. 2012;42:1261–72.CrossRefPubMedGoogle Scholar
- 26.Jessor R, Jessor SL. Problem behavior and psychosocial development: a longitudinal study of youth. New York: Academic Press; 1977.Google Scholar
- 28.Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess Winch Engl. 2007;11:1–171. iii–ivGoogle Scholar
- 36.Wyse JJ, Gordon AJ, Dobscha SK, Morasco BJ, Tiffany E, Drexler K, et al. Medications for opioid use disorder in the Department of Veterans Affairs (VA) Health Care System: historical perspective, lessons learned and next steps. Subst Abus 2018. https://doi.org/10.1080/08897077.2018.1452327.
- 37.• Yovell Y, Bar G, Mashiah M, Baruch Y, Briskman I, Asherov J, et al. Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: a randomized controlled trial. Am J Psychiatry. 2016;173:491–8. Demonstrated that buprenorphine reduces suicidality directly in non-substance abusers irrespective of concomitant antidepressant treatment.CrossRefPubMedGoogle Scholar